Jazz Pharma (JAZZ) EPS Miss Overshadowed By Settlements - UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements
May 11, 2016 6:17 AM EDTMizuho Securities upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $193.00 (from $137.00) on Xyrem Settlements.
Analyst Irina Koffler commented, "Jazz's announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for. We modeled Xyrem... More
Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line
May 10, 2016 4:08 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.26, $0.05 worse than the analyst estimate of $2.31. Revenue for the quarter came in at $336 million versus the consensus estimate of $338.86 million.
"During the first quarter of 2016, we executed on our business model by delivering strong top-... More
